Article

Old technique, new delivery

Results of a preclinical pilot study demonstrate ocular iontophoresis accelerates transfer of topically applied riboflavin into the cornea compared with conventional application, said George O. Waring IV, MD.

Orlando-Results of a preclinical pilot study demonstrate ocular iontophoresis accelerates transfer of topically applied riboflavin into the cornea compared with conventional application, said George O. Waring IV, MD.

“There is a lot of debate about the best way to deliver riboflavin to the cornea for corneal collagen crosslinking,” said Dr. Waring, medical director, Division of Ophthalmology, St. Joseph’s Translational Research Institute, Atlanta. “This proof-of-concept study indicates that iontophoretic application of riboflavin should decrease patient treatment time and may eliminate the need for corneal de-epithelialization before treatment.”

The efficacy and safety of the iontophoretic technique was investigated in an animal study in which 12 New Zealand rabbits were divided into four groups. In two groups 0.1% riboflavin was delivered with iontophoresis using application times of 3 or 5 minutes and a current of 1 mA/cm2. One group received riboflavin delivery by passive imbibition with a bioenhancer to loosen the tight junctions, and a control group underwent 5 minutes of iontophoresis with application of normal saline instead of riboflavin.

Stromal concentrations of riboflavin were measured after 15 minutes by high-performance liquid chromatography and showed the iontophoretic delivery of riboflavin depended on iontophoresis time, and the highest concentration was achieved in the 5-minute iontophoresis group. Confocal analysis of the cornea showed no irregularities in corneas where the electric current was 1 mA/cm2. Some opacities were observed when the current was increased to 2.5 mA/cm2, although they were reversible.

“Based on this study, 1 mA/cm2 appears to be a safe current level,” Dr. Waring said. “Higher currents may be considered potentially to shorten delivery time, but further studies are needed.”

For more articles in this issue of Ophthalmology Times Conference Brief click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.